Pomalidomide for Treatment of Relapsed and Refractory Multiple Myeloma
Pomalidomide is a third-generation immunomodulatory drug recommended for patients with multiple myeloma refractory to lenalidomide and bortezomib. The safety profile is optimized for application in patients with intensive and continuous anti-tumor treatment. Pomalidomide was approved by the Food and...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado: |
Practical Medicine Publishing House
2015-10-01
|
| Series: | Клиническая онкогематология |
| Assuntos: | |
| Acceso en liña: | https://bloodjournal.ru/index.php/coh/article/view/564 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|